en Epidemiology Original Article <div style="text-align: justify;"><span style="font-family:Arial;"><span style="font-size:11pt"><span style="line-height:150%"><b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black">Background: </span></span></span></b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black">Bladder cancer is the 10th most common cancer worldwide. We aimed to assess the prevalence of bladder cancer in the Kerman Province, in southeast Iran.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:150%"><b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black">Materials and Methods:</span></span></span></b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black"> In this cross-sectional study, we used data on 1272 patients with bladder cancer registered in the Kerman population-based cancer registry from 2014 to 2017. There were two parts of data including observed data, including those cases whose information was recorded by the cancer registry, and the unobserved part, including cases before the registry department, was established, to calculate the complete prevalence. The latter was estimated using modeling to be included in the prevalence calculation. The complete prevalence of three-, five-, ten-, and twenty-year of bladder cancer up to the end of 2017 was calculated using rprev package.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:150%"><b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black">Results:</span></span></span></b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black"> A total of 185 (14.54%) women and 1,087 (85.45%) men were recruited. The overall three-, five-, ten-, and twenty-year prevalence of bladder cancer at the end of 2017 was 26.54, 43.46, 80.3, and 142.36 per 100,000 inhabitants, respectively. The prevalence was estimated to be at its lowest rate among both males and females under the age of 45, and at its highest rate among those over 61 and older. In all age groups, males were affected more than females. </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:150%"><b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black">Conclusion:</span></span></span></b><span style="font-size:10.0pt"><span style="line-height:150%"><span style="color:black"> The prevalence of bladder cancer in the Kerman Province was higher than the national average and increased with age. Regarding the aging population, policies and programs for prevention, early intervention, and awareness-raising in the community about this cancer are essential.</span></span></span></span></span></span></div> Bladder Neoplasms,Prevalence,Iran, 180 186 http://johe.rums.ac.ir/browse.php?a_code=A-10-507-1&slc_lang=en&sid=1 Zahra Abdolahinia zahra.a211374@gmail.com 22400319475328460011377 22400319475328460011377 No Ph.D Student in Epidemiology, HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Kerman University of Medical Sciences Moghaddameh Mirzaee moghadameh_mirzai@yahoo.com 22400319475328460011378 22400319475328460011378 No Associate Prof., Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Kerman University of Medical Sciences Hamid Pakmanesh h_pakmanesh@yahoo.com 22400319475328460011379 22400319475328460011379 No Associate Prof., Dept., of Urology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Kerman University of Medical Sciences Azam Bazrafshan bazrafshan.a.83@gmail.com 22400319475328460011380 22400319475328460011380 No Ph.D in Medical Library and Information Sciences, Kerman Population-Based Cancer Registry (KPBCR), Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran; HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman, Iran. Institute for Futures Studies in Health Mehdi Shafiei Bafti kmushafiei@yahoo.com 22400319475328460011381 22400319475328460011381 No MD, MPH, Head of Communicable Diseases Department, Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran. Armita Shahesmaeili a.shahesmaeili@gmail.com 22400319475328460011382 22400319475328460011382 Yes 6. Associate Prof., HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Kerman University of Medical Sciences